Cargando…
Anti‐infective immunoadhesins from plants
Immunoadhesins are recombinant proteins that combine the ligand‐binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA‐approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept (Enbrel(®)),...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749143/ https://www.ncbi.nlm.nih.gov/pubmed/26242703 http://dx.doi.org/10.1111/pbi.12441 |
_version_ | 1782415231689949184 |
---|---|
author | Wycoff, Keith Maclean, James Belle, Archana Yu, Lloyd Tran, Y Roy, Chad Hayden, Frederick |
author_facet | Wycoff, Keith Maclean, James Belle, Archana Yu, Lloyd Tran, Y Roy, Chad Hayden, Frederick |
author_sort | Wycoff, Keith |
collection | PubMed |
description | Immunoadhesins are recombinant proteins that combine the ligand‐binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA‐approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept (Enbrel(®)), which interferes with the binding of tumour necrosis factor (TNF) to the TNF‐alpha receptor and is used to treat inflammatory diseases such as rheumatoid arthritis. Like antibodies, immunoadhesins have long circulating half‐lives, are readily purified by affinity‐based methods and have the avidity advantages conferred by bivalency. Immunoadhesins that incorporate normal cellular receptors for viruses or bacterial toxins hold great, but as yet unrealized, potential for treating infectious disease. As decoy receptors, immunoadhesins have potential advantages over pathogen‐targeted monoclonal antibodies. Planet Biotechnology has specialized in developing anti‐infective immunoadhesins using plant expression systems. An immunoadhesin incorporating the cellular receptor for anthrax toxin, CMG2, potently blocks toxin activity in vitro and protects animals against inhalational anthrax. An immunoadhesin based on the receptor for human rhinovirus, ICAM‐1, potently blocks infection of human cells by one of the major causes of the common cold. An immunoadhesin targeting the MERS coronavirus is in an early stage of development. We describe here the unique challenges involved in designing and developing immunoadhesins targeting infectious diseases in the hope of inspiring further research into this promising class of drugs. |
format | Online Article Text |
id | pubmed-4749143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47491432016-02-10 Anti‐infective immunoadhesins from plants Wycoff, Keith Maclean, James Belle, Archana Yu, Lloyd Tran, Y Roy, Chad Hayden, Frederick Plant Biotechnol J Review Articles Immunoadhesins are recombinant proteins that combine the ligand‐binding region of a receptor or adhesion molecule with immunoglobulin constant domains. All FDA‐approved immunoadhesins are designed to modulate the interaction of a human receptor with its normal ligand, such as Etanercept (Enbrel(®)), which interferes with the binding of tumour necrosis factor (TNF) to the TNF‐alpha receptor and is used to treat inflammatory diseases such as rheumatoid arthritis. Like antibodies, immunoadhesins have long circulating half‐lives, are readily purified by affinity‐based methods and have the avidity advantages conferred by bivalency. Immunoadhesins that incorporate normal cellular receptors for viruses or bacterial toxins hold great, but as yet unrealized, potential for treating infectious disease. As decoy receptors, immunoadhesins have potential advantages over pathogen‐targeted monoclonal antibodies. Planet Biotechnology has specialized in developing anti‐infective immunoadhesins using plant expression systems. An immunoadhesin incorporating the cellular receptor for anthrax toxin, CMG2, potently blocks toxin activity in vitro and protects animals against inhalational anthrax. An immunoadhesin based on the receptor for human rhinovirus, ICAM‐1, potently blocks infection of human cells by one of the major causes of the common cold. An immunoadhesin targeting the MERS coronavirus is in an early stage of development. We describe here the unique challenges involved in designing and developing immunoadhesins targeting infectious diseases in the hope of inspiring further research into this promising class of drugs. John Wiley and Sons Inc. 2015-10 2015-08-04 /pmc/articles/PMC4749143/ /pubmed/26242703 http://dx.doi.org/10.1111/pbi.12441 Text en © 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
spellingShingle | Review Articles Wycoff, Keith Maclean, James Belle, Archana Yu, Lloyd Tran, Y Roy, Chad Hayden, Frederick Anti‐infective immunoadhesins from plants |
title | Anti‐infective immunoadhesins from plants |
title_full | Anti‐infective immunoadhesins from plants |
title_fullStr | Anti‐infective immunoadhesins from plants |
title_full_unstemmed | Anti‐infective immunoadhesins from plants |
title_short | Anti‐infective immunoadhesins from plants |
title_sort | anti‐infective immunoadhesins from plants |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749143/ https://www.ncbi.nlm.nih.gov/pubmed/26242703 http://dx.doi.org/10.1111/pbi.12441 |
work_keys_str_mv | AT wycoffkeith antiinfectiveimmunoadhesinsfromplants AT macleanjames antiinfectiveimmunoadhesinsfromplants AT bellearchana antiinfectiveimmunoadhesinsfromplants AT yulloyd antiinfectiveimmunoadhesinsfromplants AT trany antiinfectiveimmunoadhesinsfromplants AT roychad antiinfectiveimmunoadhesinsfromplants AT haydenfrederick antiinfectiveimmunoadhesinsfromplants |